###### Key messages

-   Could the airway microbiota be a source of predictive biomarkers of early *P* *seudomonas* *aeruginosa* pulmonary infection?

-   The airway microbiota might be more or less permissive to *P. aeruginosa* in cystic fibrosis (CF) airways.

-   Based on a cohort study, we found the first candidate biomarker predictive of *P. aeruginosa* pulmonary infection in CF.

Introduction {#s1}
============

Respiratory polymicrobial infections play a major role in cystic fibrosis (CF) progression and the acquisition of bacterial pathogens during the course of the disease is now well described. After \~25 years old, the establishment of CF pathogens is usually completed, *P. aeruginosa* being the most predominant species in CF lung. *P. aeruginosa* has a negative impact on pulmonary function promoting more frequent acute exacerbations. *P. aeruginosa* is linked to worsened prognosis for patients with CF; they have a decreased life expectancy and experience a more rapid decline in pulmonary function compared with non-colonised patients. At the stage of chronic infection, the eradication of the pathogen is impossible; this places all the hopes of treatment at the early stage of the infection. Indeed, the chances to successfully eradicate *P. aeruginosa* are the most important in the early stages of *P. aeruginosa* colonisation.

Improvement in the median survival of patients with CF is correlated with early antibiotic therapy in patients colonised with *P. aeruginosa*, the eradication success being essentially dependent on how early *P. aeruginosa* is detected.[@R1] As early *P. aeruginosa* pulmonary infection is completely asymptomatic in most cases,[@R2] the monitoring is based on systematic microbiological analysis. In this aim, *P. aeruginosa* quantitative PCR (qPCR) detection was shown to be relevant in patients' follow-up.[@R3] For the coming years, one challenge is to decipher the factors involved in the early onset of *P. aeruginosa* colonisation. Demographic and environmental factors were shown to increase the risk of *P. aeruginosa* acquisition, but are not precise enough to predict the risk of *P. aeruginosa* early colonisation.[@R4]

In the framework of the present study, we hypothesised that lung commensal microbiota could be associated with *P. aeruginosa* early colonisation in CF. In the precision medicine era, the aim of this study was to find biomarkers for providing close monitoring to CF patients more at risk of early *P. aeruginosa* colonisation and improving clinical benefit of successful early *P. aeruginosa* eradication.

Methods {#s2}
=======

Patient cohort, inclusion criteria and global data {#s2-1}
--------------------------------------------------

A 3-year prospective multicentre study (PYOMUCO study) was conducted in Western France to assess the time saved in the detection of *P. aeruginosa* in patients with CF by qPCR compared with culture detection methods.[@R3] Only patients *P. aeruginosa* free for at least 1 year were included. The cohort was divided into two groups at the end of the follow-up; group 1 contained patients who remained free of *P. aeruginosa* while patients from group 2 became positive in culture for *P. aeruginosa* during the follow-up. For each patient, sputum was collected every 3 months up to the first *P. aeruginosa* positivity in culture. For this ancillary study, 33 patients with CF of the PYOMUCO cohort were selected as follows: 20 patients from the 36 who became *P. aeruginosa*-positive at the end of the follow-up, and 13 patients from the 28 who remained *P. aeruginosa-*negative both in qPCR and culture.[@R3] The analysis of airway microbiota was performed retrospectively on spontaneous sputum samples collected at two time points: at enrolment (T0) and at the end of the follow-up (Tf) ([figure 1](#F1){ref-type="fig"}). Overall, 75.7% of the samples originated from a paediatric population (\<18 years old at sampling time). Clinical and biological data were collected at each sampling time (see [online supplementary table S1](#SP3){ref-type="supplementary-material"}). The majority of patients were homozygous (n=21, 63.6%) or heterozygous (n=12, 36.4%) for the F508del-CFTR mutation. Four clinical states were defined: baseline clinical state, pulmonary exacerbation, treatment for exacerbation and recovery (BETR categories). Sputum sample quality was verified by cytological examination as previously described.[@R3] *P. aeruginosa* was quantified using qPCR and a culture-based method, as previously described.[@R3] In order to confirm *Porphyromonas* distribution with respect to *P. aeruginosa* colonisation throughout the follow-up, *P. catoniae* absolute quantification was carried out with qPCR on 52 additional patients of the PYOMUCO cohort.
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![Two-step approach of the study. Samples were issued from the PYOMUCO cohort study whose patients (n=96), initially (T0) all *Pseudomonas aeruginosa* (PA) free for at least 1 year, were separated into two groups (group 1 and group 2) according to their *P. aeruginosa* status at the end of the follow-up (Tf).[@R3] Group 1 patients remained negative, whereas group 2 patients became positive. In a first step carried out in a first set of patients (n=33), bacterial biomarkers associated with *P. aeruginosa* were screened by 16S-targeted metagenomics; a candidate biomarker (*Porphyromonas catoniae*) was revealed. In a second step, distribution of the candidate biomarker according to the two groups of patients was verified by quantitative PCR (qPCR) on a second set of patients (n=52) coming from the same cohort. CF, cystic fibrosis.](bmjresp-2018-000374f01){#F1}

Targeted metagenomics and *P. catoniae* absolute quantification in sputum samples {#s2-2}
---------------------------------------------------------------------------------

Total DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN, Courtabœuf, France) as previously described.[@R5] For bacterial diversity assessment, barcoded high-throughput 454 pyrosequencing was performed on the amplified V3 and V4 hypervariable regions of the 16S rRNA gene, and data analysed as previously described (Bioproject PRJNA445243).[@R5] The absolute quantification of *P. catoniae* was performed using a validated qPCR scheme with the standard curve method. The qPCR was set up on the ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, California, USA) with SYBR Green, and original primers (sense: 5′-GTGTCTTCGCCCAGCTTACT-3′; antisense: 5′-AGGATGCGGCGGGTTTCA-3′) targeting the *rplb* gene. PCR reactions were carried out in a total volume of 25 µL with 12.5 µL of Select Mastermix (Applied Biosystems), and a temperature profile of 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, 60°C for 60 s, 95°C for 30 s and 60°C for 15 s.

Bioinformatics and statistical analyses {#s2-3}
---------------------------------------

Sequences were analysed with the standard UPARSE pipeline according to Edgar's instructions as previously described[@R5] (see [online supplementary file 1](#SP1){ref-type="supplementary-material"}).
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Statistical comparison between groups was performed with the Mann-Whitney U and Kruskal-Wallis tests, and linear discriminant analysis effect size (LEfSe) was used to elucidate bacterial taxa associated with group 1 or group 2 patients. The false discovery rate was calculated to correct for multiple hypothesis testing. Principal component analysis and clustering analysis were computed on different distance matrix to document the presence of enterotype-like clusters in airway CF microbiota.[@R7] These clusters were named pulmotypes.

Results {#s3}
=======

The cohort samples clustered into three pulmotypes (p=0.001, Kruskal-Wallis test) driven by the differences in relative abundance of three dominant genera, *Streptococcus*, *Haemophilus* and *Staphylococcus*, as well as other co-occurring genera (see [online supplementary figure S1](#SP2){ref-type="supplementary-material"}). Overall, 11 predominant genera (relative abundance ≥1%) were found, including *Porphyromonas* which abundance varied between 2.5% and 6.9% depending on the pulmotype. Random forest analysis revealed a significant connexion between relative abundance of *Pseudomonas* and *Porphyromonas* ([figure 2A](#F2){ref-type="fig"}). Interestingly, in group 1 patients who remained uninfected by *P. aeruginosa* during the follow-up ([figure 2B](#F2){ref-type="fig"}), *Porphyromonas* relative abundance at T0 was significantly higher than in group 2 patients (p\<0.001, Mann-Whitney U test) ([figure 2C](#F2){ref-type="fig"}).
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![Inverse correlation between *Pseudomonas aeruginosa* and *Porphyromonas* revealed by both 16S rRNA microbiota study and quantitative PCR study in the two groups of patients with cystic fibrosis: group 1 patients (G1) remained *P. aeruginosa*-negative from the initial visit (T0) to the last one (Tf); group 2 patients (G2), initially negative at T0, became *P. aeruginosa*-positive at Tf. (A) Results of random forest analysis showing the 15 taxa that contributed the most to each group based on the measure of mean decrease in accuracy. (B) Normalised abundance of *P. aeruginosa* in each group at the two time points. (C) Normalised abundance of *Porphyromonas* in each group at the two time points. (D) Absolute quantification of *P. catoniae* in each group (G1, G2) at the two time points (T0, Tf); a third time point was added (Tx) that corresponded to the visit which preceded the last one (Tf).](bmjresp-2018-000374f02){#F2}

As *Porphyromonas* reads mainly corresponded to *P. catoniae* species, we focused on this bacterial species. In order to check the distribution of *P. catoniae* according to the patient group, we quantified *P. catoniae* by qPCR in another set of patients from the PYOMUCO cohort. For group 1 patients, we did not observe any statistical difference in *P. catoniae* population between the first (T0) and last sample (Tf) (p=0.41, t-test). Conversely, group 2 patients showed a significant drop in *P. catoniae* population (p=0.039, t-test) ([figure 2D](#F2){ref-type="fig"}). Then, we compared patients according to their *P. catoniae* population before *P. aeruginosa* colonisation. Group 1 had a significantly higher initial *P. catoniae* absolute quantity than group 2 (p=0.026). Finally, we tested the predictive power of *P. catoniae*. To do this, we analysed the susceptibility of patients with CF to acquire *P. aeruginosa* according to the presence or absence of *P. catoniae* in the penultimate sputum (Tx) ([figure 2D](#F2){ref-type="fig"}). We observed that 40.7% of patients without *P. catoniae* developed a *P. aeruginosa* infection the visit after (3 months later), while only 24% of patients positive for *P. catoniae* developed the infection ([table 1](#T1){ref-type="table"}).

###### 

Table of contingency showing the distribution of patients with cystic fibrosis (n=52) according to their *Porphyromonas catoniae* colonisation status during the follow-up with respect to *Pseudomonas aeruginosa* status at the end of the follow-up

  Patient group\*   *P. catoniae* colonisation†   
  ----------------- ----------------------------- ----------
  Group 1           16 (59.3%)                    19 (46%)
  Group 2           11 (40.7%)                    6 (24%)
  Total             27                            25

\*Group 1, patients who remained *P. aeruginosa-*negative; group 2, patients who became *P. aeruginosa*-positive; Hazard Ratio 1.7.

†Detection carried out on the penultimate sputum sample.

Discussion {#s4}
==========

Bacteria from the *Porphyromonas* genus are anaerobic commensals of the core pulmonary microbiota in healthy people[@R8] and also described as part of the CF pulmonary core microbiota.[@R5] Characterisation of bronchoalveolar lavages' microbiota in infants with asymptomatic CF retrieved *Porphyromonas* as one of the six highest abundant taxa.[@R10]

Looking into details at the taxonomic affiliation of *Porphyromonas* reads, the vast majority of them were affiliated to *P. catoniae*, which is in agreement with other culture-dependent and culture-independent studies.[@R11] Interestingly, in another study, the abundance of *Porphyromonas* was significantly lower in sputa of patients with chronic obstructive pulmonary disease as compared with healthy subjects.[@R8] Moreover, a decrease in *P. catoniae* abundance was observed during exacerbations,[@R13] and after antibiotic treatment, the abundance of *P. catoniae* returned to a baseline identical to that of the pre-exacerbation period.[@R13] These results also echo a previous observation in patients with CF under the CFTR potentiator drug. Indeed, a sustained increase of *Porphyromonas* relative abundance after initiation of ivacaftor was stated, which was positively correlated with the percentage of predicted FEV~1~.[@R6]

The present study gave clues on the power of *P. catoniae* in predicting the risk of *P. aeruginosa* acquisition. Indeed, *P. catoniae* colonisation was associated with a lower risk of *P. aeruginosa* infection. Conversely, patients harbouring no *P. catoniae* within their airway microbiota showed 1.7-fold risk of acquiring *P. aeruginosa* later.

Taken together, these results suggest that *P. catoniae* may be considered as a favourable prognostic biomarker in CF. Further prospective studies on replication cohorts are needed to define the benefit provided by *P. catoniae* quantification in identifying patients with a higher risk of *P. aeruginosa* infection. In case of confirmation, we suggest to perform molecular quantifications of both *P. catoniae* and *P. aeruginosa* as part of the CF diagnosis toolbox in order to enlarge the 'window of opportunity' in the management of *P. aeruginosa* infection.

To conclude, this study showed the crucial importance of microbiota data in the management of patients with CF. In the personalised and precision medicine era, microbiota-based study could identify signatures that could be useful in predicting the CF progression. Identification of new bacteria of interest opens the possibility of using them as prognostic biomarkers or as companion diagnostic test. Further cohort studies are needed to validate these findings and to address the question of causality. The influence of the input microbiota on CF progression during early life has also to be investigated. In the not-too-distant future, study of both biochemical and microbial signatures will constitute new approaches to understand CF microbiology.
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